Suzhou Jinmeng Biotechnology

Suzhou Jinmeng Biotechnology is a Chinese biotechnology company and a subsidiary of Haisco Pharmaceutical Group, specializing in the development and manufacturing of recombinant protein therapeutics. Based in the Suzhou Industrial Park, the company focuses on high-value biologics including biosimilars and innovative long-acting proteins for metabolic and endocrine disorders. Its pipeline features advanced programs such as recombinant human serum albumin (HSK-P1101) and parathyroid hormone analogs (HSK-P1102), both of which have reached late-stage clinical development. Jinmeng Biotech operates state-of-the-art R&D facilities and GMP-compliant manufacturing lines to support its internal pipeline and large-scale production needs. The company leverages its proprietary recombinant protein expression and purification platforms to address unmet medical needs in hypoalbuminemia, osteoporosis, and diabetes. As a core biological drug base for its parent group, Suzhou Jinmeng is positioned to become a significant player in the global biopharmaceutical market.